<DOC>
	<DOC>NCT02459899</DOC>
	<brief_summary>The primary objective of this study is to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.</brief_summary>
	<brief_title>Dose-ranging Study in Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Patient has given written informed consent to participate in the study in accordance with local regulations Adult patients 18 years and older with a diagnosis of T1D made at least 1 year prior to informed consent Patients are being treated with insulin or insulin analog delivered via CSII or MDI At the Screening Visit, A1C must be between 7.0% to 10.0% Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test Use of antidiabetic agent other than insulin or insulin analog at the time of screening Use of sodiumglucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening Chronic systemic corticosteroid use Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>